HOME >> BIOLOGY >> NEWS
UT Southwestern researchers find gene mutation that leads to 'broken hearts'

Dallas -- July 20, 2006 -- Researchers at UT Southwestern Medical Center have identified a group of fruit fly gene mutations responsible for "broken hearts" in the embryonic stages of development, a discovery that could help identify genes that cause human heart defects.

"We engineered a fruit fly so that the heart would glow in the dark and found a new type of malformation, completely unexpectedly," said Dr. Eric Olson, chairman of molecular biology at UT Southwestern and senior author of the study appearing in today's issue of Science. "We coined the term 'brokenhearted' for this defect because two kinds of cardiac cells separated, thus causing the heart to fall apart, with a loss of heart function and embryonic death."

The heart is the first organ to form and function in the embryo. Abnormalities in the complex process of heart formation result in congenital heart defects, the most common birth defects in humans afflicting about 1 percent of newborns. Because the events of heart formation are very similar throughout the animal world, the fruit fly is a useful model to study the causes of heart defects in mammals, Dr. Olson said.

The researchers found that mutations in genes encoding enzymes in a pathway for synthesis of a small lipid caused this broken heart defect in fruit flies. One of these enzymes, HMG CoA reductase, also plays a key role in the synthesis of cholesterol in humans. In fruit flies, these enzymes are required to generate a small lipid to modify a signaling protein, which is required for heart formation. The study suggests the involvement of the same biochemical pathway in human heart formation and congenital heart disease.

"We were surprised to discover that a group of enzymes involved in lipid synthesis plays a previously unrecognized role in assembling the heart. The same mechanism is likely to be involved in human-heart development," said Dr. Olson, director of the Nancy B. and Jake L. Hamo
'"/>

Contact: Katherine Morales
katherine.morales@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
20-Jul-2006


Page: 1 2

Related biology news :

1. UT Southwestern joins national clinical trial to uncover long-term effects of West Nile virus
2. UT Southwestern leaders to receive national award for medical research accomplishments
3. UT Southwestern scientist receives NIH Directors Pioneer Award
4. UT Southwestern scientist named Keck Foundation Distinguished Young Scholar in Medical Research
5. Plague agent helps UT Southwestern researchers find novel signaling system in cells
6. One of the nations first 7-Tesla magnetic resonance imaging devices for human studies planned at UT Southwestern Medical Center
7. DNA end caps may lead to cancer treatments, UT Southwestern researchers report
8. UT Southwestern scientist honored among best in Texas research
9. UT Southwestern scientist receives international award for pediatric research
10. UT Southwestern physician-researcher wins international award for lipid research
11. UT Southwestern scientist elected to National Academy of Sciences Institute of Medicine

Post Your Comments:
(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
(Date:5/11/2015)... Ohio , May 11, 2015  Through a well-rounded ... Ohio had a strong showing at AUVSI,s Unmanned ... These representatives of Ohio,s UAS industry ... and abroad from all points along the UAS ecosystem. ... Development Coalition,s (DDC) Vice President for Aerospace Rich Knoll ...
(Date:5/10/2015)... GOTHENBURG, Sweden , May 11, 2015 ... touch fingerprint sensors FPC1025 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... the sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + 1 000 ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
(Date:5/21/2015)... Specialty Pharmacy Times has completed its ... BPA Worldwide as a business publication member. As ... for Specialty Pharmacy Times based on business/distribution, demographics ... member of BPA Worldwide, Specialty Pharmacy Times shows ... the most reliable, unequaled data,” said Chris Hennessy, ...
(Date:5/21/2015)... 21, 2015  The EveryLife Foundation for Rare ... and Amy Klobuchar (D-MN) today for ... & Treatments, or OPEN ACT. Supported ... organizations, this bipartisan legislation promises to rapidly bring ... rare disease patients by incentivizing drug makers to ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Veolia’s environmental monitoring technology division, ... distribution agreement with VWR to distribute TECTA™ B16, ... than 160 years of experience, VWR, a leading ... and production facilities, has cultivated a value proposition ... to enable science. Endetec’s TECTA™ B16, combines ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
Cached News: